OpenClaim

Tralokinumab Side Effects

The most commonly reported side effects of tralokinumab include dermatitis atopic, pruritus, and rash, based on 5,157 FDA adverse event reports from 2018 to 2025. 13.0% of reports found the drug to be ineffective.

#1 Reported: Dermatitis AtopicAll side effects ↓Top Co-Medication: DupilumabDrug interactions ↓72% of Reports Are AdultDemographics ↓

Tralokinumab side effects

Percentages show how often each reaction appears relative to total reports for tralokinumab.

1
Dermatitis Atopic14.3%740
2
Drug Ineffective13.0%670
3
Pruritus10.7%553
4
Rash7.5%389
5
Injection Site Pain5.1%261
6
Eczema4.5%231
7
Dry Skin4.2%217
8
Erythema3.5%179
9
Injection Site Erythema3.2%164
10
Injection Site Pruritus2.8%145
11
Product Use In Unapproved Indication2.8%144
12
Injection Site Swelling2.7%140
13
Arthralgia2.7%139
14
Ocular Hyperaemia2.6%136
15
Eye Pruritus2.6%136

These are voluntary reports and do not establish that tralokinumab caused these reactions.

Report severity

15.7%Serious809 reports
5.8%Hospitalizations299 reports
1.4%Fatal70 reports

Seriousness is determined by the reporter, not by OpenClaim.

Tralokinumab drug interactions

Other drugs that appear in adverse event reports alongside tralokinumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.

Also suspected

1
Dupilumab12.9%663
2
Upadacitinib0.6%29
3
Tacrolimus0.2%12
4
Abrocitinib0.2%11
5
Methotrexate0.2%10
6
Baricitinib0.1%7
7
Clobetasol-propionate0.1%6
8
Cyclosporine0.1%6
9
Omalizumab0.1%6
10
Triamcinolone<0.1%5
11
Levonorgestrel<0.1%5
12
Crisaborole<0.1%5
13
Prednisone<0.1%5
14
Nemolizumab-ilto<0.1%5
15
Abatacept<0.1%4

Taken alongside

1
Triamcinolone2.2%112
2
Albuterol1.9%99
3
Ergocalciferol1.8%93
4
Clobetasol-propionate1.7%88
5
Cetirizine-hydrochloride1.4%74
6
Tacrolimus1.4%73
7
Omeprazole1.4%72
8
Hydroxyzine1.4%71
9
Amlodipine1.3%66
10
Atorvastatin-calcium1.2%64
11
Fluticasone1.2%63
12
Rosuvastatin1.2%63
13
Aspirin1.2%62
14
Levothyroxine-sodium1.2%60
15
Prednisone1.1%59

Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.

Who reports tralokinumab side effects

61.5% of tralokinumab adverse event reports involve female patients and 36.7% involve male patients. The largest age group is adult at 72%. These figures reflect who reports side effects, not underlying risk.

Sex

Female61.5%
Male36.7%
Unknown1.8%

Age group

< 2<0.1%
2–110.2%
12–173.8%
18–6472.2%
65+23.8%

What is tralokinumab used for

Conditions and purposes for which patients were taking tralokinumab when the adverse event was reported.

AcneAdenomyosisAdverse Drug ReactionAnkylosing SpondylitisAsthmaAtrophic VulvovaginitisChronic Myeloid Leukaemia (in Remission)Chronic Spontaneous UrticariaConjunctivitisDermatitis AtopicDermatitisDermatitis AllergicDermatitis AtopicDermatitis ContactDermatitis Psoriasiform

Showing 15 of 66 indications

Tralokinumab brand names and reporting trend

Tralokinumab is sold under the brand name Adbry.

Brand names

Adbry137

Quarterly reports (2018–2025)

2018202220242025

An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.

Taking tralokinumab with another medication?

Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.

Check my medications